HGEN News and Press, Humanigen Inc. From 07/06/22

Clinical-stage biotech Humanigen ( NASDAQ: HGEN ) rose more than 10% on Wednesday after the company announced a peer-reviewed publication of data supporting its investigational COVID-19 therapy lenzilumab. The publication in the medical journal Thorax was based on the data...

A sub-analysis of the Phase 3 LIVE-AIR study of lenzilumab showed a strong correlation between C-reactive protein (CRP) and outcomes with lenzilumab treatment with the greatest clinical benefit experienced by patients with baseline CRP<150 mg/L In these patients, likelihood of ...

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, confirms that notice was received today...

A new 2022/23 study continues the trading studies from 2017 testing abnormal Russell Index reconstitution returns from scholarly literature. Since 2017 the best return results from a price momentum test generated +57.90% in the first six months and average gains reached +29.04% in the...

SRAX (NASDAQ: SRAX) , a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (“SaaS”) platform, through Sequire, its SaaS platform, hosted the 2022 LD Micro Invitational. The invitation was held June 7–9, 20...

Redbox Entertainment (RDBXW) +70%. Sidus Space (SIDU) +45%. Redbox Entertainment (RDBX) +18%. Seres Therapeutics (MCRB) +13%. Checkpoint Therapeutics (CKPT) +12%. Mobiquity Technologies (MOBQ) +9%. Humanigen (HGEN) +6% as it enters pact with PCI Pharma Services in UK for lenzilumab....

Humanigen (NASDAQ:HGEN) is up 2.2% premarket after the firm has entered into an agreement with PCI Pharma Services, a leading integrated global contract development manufacturing organization (CDMO), to provide importation, release and commercialization services in the United K...

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced it entered into an agreement with PCI Pharma Services (PCI), a l...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Rigel Pharmaceuticals (RIGL) -49% after reports top-line results from FORWARD Phase 3 trial of Fostamatinib in patients with warm autoimmune hemolytic anemia. AeroClean Technologies (AERC) -17%. The Scotts Miracle-Gro SMG -13% as it cuts revenue and EPS outlook for FY2022....